Burden of allergic rhinitis: Allergies in America, Latin America, and Asia-Pacific adult surveys

Latin America experienced economic ups and downs in the past decade, and faces a gloomy outlook for 2015–2020. This chapter first delineates the near-term growth prospects for the region, examining the subregional patterns closely with three national cases—Argentina, Brazil, and Venezuela—and analyzing the external constraints for the region’s economic growth. It then examines the major challenges ahead for the region with analysis of Latin America’s economic relationship with the United States and China, respectively. On the one hand, while the U.S.’s current bilateral approach leaves the economic relationship with the region fragmented, the economic and trade cooperation between the U.S. and Latin America can be strengthened through fostering productive integration and the development of regional value chains oriented toward the U.S. market. On the other hand, China’s growing presence in the region poses challenges to Latin America countries, namely achieving export diversification, diversification of Chinese investments in the region, and Latin investment in China and Asia-Pacific.

Download Full-text

Latin America in Asia-Pacific Perspective

10.4324/9780429267611-16 ◽

2021 ◽

pp. 251-278

Author(s):

Evelyn Hu-Dehart

Keyword(s):

Latin America ◽

Asia Pacific

Download Full-text

ASIA PACIFIC SURVEY OF PHYSICIANS ON ASTHMA AND ALLERGIC RHINITIS (ASPAIR): DATA FOR GENERAL PRACTITIONERS COMPARED TO PAEDIATRICIANS

Respirology ◽

10.1111/resp.13419_187 ◽

2018 ◽

Vol 23 ◽

pp. 76-76

Keyword(s):

Allergic Rhinitis ◽

General Practitioners ◽

Asia Pacific

Download Full-text

Surveillance of Omadacycline Activity against Clinical Isolates from a Global Collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011

Antimicrobial Agents and Chemotherapy ◽

10.1128/aac.00018-17 ◽

2017 ◽

Vol 61 (5) ◽

Cited By ~ 30

Author(s):

Michael A. Pfaller ◽

Michael D. Huband ◽

Paul R. Rhomberg ◽

Robert K. Flamm

Keyword(s):

Latin America ◽

North America ◽

Klebsiella Oxytoca ◽

Enterobacter Aerogenes ◽

Community Acquired Pneumonia ◽

Asia Pacific ◽

Gram Positive ◽

Gram Negative ◽

Content Type ◽

Viridans Group Streptococci

ABSTRACT Omadacycline is a broad-spectrum aminomethylcycline in late-stage clinical development for the treatment of acute bacterial skin and skin structure infections and community-acquired pneumonia as an oral and an intravenous once-daily formulation. In this study, omadacycline and comparators were tested against 69,246 nonduplicate bacterial isolates collected prospectively during 2010 and 2011 from medical centers in Asia-Pacific (11,397 isolates), Europe (23,490 isolates), Latin America (8,038 isolates), and North America (26,321 isolates). Omadacycline was tested by broth microdilution following Clinical and Laboratory Standards Institute M07-A10 (2015) methods. A total of 99.9% of Staphylococcus aureus isolates were inhibited by ≤2 μg/ml of omadacycline (MIC50/90, 0.12/0.25 μg/ml), including 100.0% of methicillin-susceptible S. aureus isolates and 99.8% of methicillin-resistant S. aureus isolates. Omadacycline potencies were comparable for Streptococcus pneumoniae (MIC50/90, 0.06/0.06 μg/ml), viridans group streptococci (MIC50/90, 0.06/0.12 μg/ml), and beta-hemolytic streptococci (MIC50/90, 0.06/0.12 μg/ml) regardless of species and susceptibility to penicillin. Omadacycline was active against Enterobacteriaceae and was most active against Escherichia coli (MIC50/90, 0.5/2 μg/ml), Enterobacter aerogenes (MIC50/90, 2/4 μg/ml), Klebsiella oxytoca (MIC50/90, 1/4 μg/ml), and Citrobacter spp. (MIC50/90, 1/4 μg/ml). Omadacycline was active against Haemophilus influenzae (MIC50/90, 1/1 μg/ml) regardless of β-lactamase status and against Moraxella catarrhalis (MIC50/90, 0.12/0.25 μg/ml). The potent activity of omadacycline against Gram-positive and Gram-negative bacteria indicates that omadacycline merits further study in serious infections in which multidrug resistance and mixed Gram-positive and Gram-negative infections may be a concern.

Download Full-text

Antimicrobial Susceptibility of Streptococcus pneumoniae from North America, Europe, Latin America, and the Asia-Pacific Region: Results From 20 Years of the SENTRY Antimicrobial Surveillance Program (1997–2016)

Open Forum Infectious Diseases ◽

10.1093/ofid/ofy263 ◽

2019 ◽

Vol 6 (Supplement_1) ◽

pp. S14-S23 ◽

Cited By ~ 12

Author(s):

Helio S Sader ◽

Rodrigo E Mendes ◽

Jennifer Le ◽

Gerald Denys ◽

Robert K Flamm ◽

...

Keyword(s):

Latin America ◽

Streptococcus Pneumoniae ◽

North America ◽

Antimicrobial Susceptibility ◽

Asia Pacific ◽

Surveillance Program ◽

Pacific Region ◽

Asia Pacific Region ◽

Antimicrobial Surveillance ◽

Tract Infections

Abstract Background The SENTRY Antimicrobial Surveillance Program monitors the frequency of occurrence and antimicrobial susceptibility of organisms from various infection types worldwide. In this investigation, we evaluated the antimicrobial susceptibility of Streptococcus pneumoniae isolates collected worldwide over 20 years (1997–2016). Methods A total of 65 993 isolates were consecutively collected (1 per infection episode) from North America (NA; n = 34 626; 2 nations), Europe (EUR; n = 19 123; 23 nations), the Asia-Pacific region (APAC; n = 7111; 10 nations), and Latin America (LATAM; n = 5133; 7 nations) and tested for susceptibility using reference broth microdilution methods. Resistant subgroups included multidrug-resistant (MDR; nonsusceptible to ≥3 classes of agents) and extensively drug-resistant (XDR; nonsusceptible to ≥5 classes). Results The isolates were collected primarily from respiratory tract infections (77.3%), and 25.4% were from pediatric patients. Penicillin susceptibility (≤0.06 mg/L) rates varied from 70.7% in EUR to 52.4% in APAC for all years combined. In NA, there was a slight improvement in susceptibility for the first few years of the program, from 66.5% in 1997–1998 to 69.4% in 1999–2000, followed by a decline until 2011–2012 (57.0%). Similar declines in penicillin susceptibility rates were observed in all regions, with the lowest rates of 67.3% in EUR (2011–2012), 41.6% in the APAC region (2007–2008), and 48.2% in LATAM (2013–2014). These declines were followed by improved susceptibility rates in all regions in later program years, with susceptibility rates of 55.6% to 71.8% in 2015–2016 (65.8% overall). Susceptibility rates to ceftriaxone, erythromycin, clindamycin, tetracycline, and trimethoprim-sulfamethoxazole followed a similar pattern, with a decrease in the first 12–14 years and a continued increase in the last 6–8 years of the program. MDR and XDR frequencies were highest in APAC (49.8% and 17.3% overall, respectively) and lowest in LATAM (10.8% and 1.9% overall, respectively). The most active agents for MDR/XDR isolates were ceftaroline (99.7%/99.1% susceptible), tigecycline (96.8%/95.9% susceptible), linezolid (100.0%/100.0% susceptible), and vancomycin (100.0%/100.0% susceptible). Conclusions S. pneumoniae susceptibility to many antibiotics increased in all regions in the last few years, and these increases may be related to PCV13 immunization, which was introduced in 2010.

Download Full-text

Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019

Journal of Antimicrobial Chemotherapy ◽

10.1093/jac/dkaa504 ◽

2020 ◽

Author(s):

Helio S Sader ◽

Cecilia G Carvalhaes ◽

S J Ryan Arends ◽

Mariana Castanheira ◽

Rodrigo E Mendes

Keyword(s):

Latin America ◽

Western Europe ◽

Multidrug Resistant ◽

Clinical Development ◽

Asia Pacific ◽

Asia Pacific Region ◽

Carbapenem Resistant ◽

Serious Infections ◽

Susceptibility Tests

Abstract Background Aztreonam is a monobactam stable to hydrolysis by metallo-β-lactamases (MBLs) and avibactam is a non-β-lactam β-lactamase inhibitor that effectively inhibits serine carbapenemases (CPs). Aztreonam/avibactam is under clinical development for treatment of serious infections caused by Gram-negative bacteria, including MBL-producers. Objectives To evaluate the in vitro activity of aztreonam/avibactam against clinical Enterobacterales isolates. Methods 8787 Enterobacterales were collected consecutively from 64 medical centres located in Western Europe (W-EU; n = 4616; 26 centres in 10 nations), Eastern Europe (E-EU; n = 1554; 11 centres in 9 nations), the Asia-Pacific region (APAC; n = 1456; 17 centres in 9 nations), and Latin America (LATAM; n = 1161; 10 centres in 6 nations). Susceptibility tests were performed by reference broth microdilution methods and interpreted according to EUCAST criteria. Results 99.9% of isolates were inhibited at aztreonam/avibactam MIC of ≤8 mg/L (MIC50/90, ≤0.03/0.12 mg/L), including 99.7% of carbapenem-resistant (CRE; n = 396; MIC50/90, 0.25/0.5 mg/L) and 99.7% of multidrug-resistant isolates (n = 1706; MIC50/90, 0.06/0.5 mg/L). CRE rates were 1.2%, 12.9%, 5.2%, and 5.8% in W-EU, E-EU, APAC, and LATAM, respectively (4.5% overall). A CP was identified in 90.2% of CRE isolates. The most common CPs were variants of KPC (35.9% of CRE), NDM (29.0%), and OXA-48 (26.8%). The highest aztreonam/avibactam MIC value among MBL-producers (n = 110; MIC50/90, 0.12/0.5 mg/L) was 2 mg/L. Susceptibility rates for ceftriaxone, meropenem, levofloxacin, and amikacin were highest in W-EU (80.9%, 99.0%, 80.7% and 97.9%, respectively) and lowest in E-EU (52.0%, 88.9%, 54.1%, and 84.2%, respectively). Conclusions Our results support clinical development of aztreonam/avibactam to treat infections caused by Enterobacterales, including MBL-producers.

Download Full-text